Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMin FangHEHarry P. ErbaCYCecilia C.S. Yeung

Discussion

Loading...

Member takes

Overview

Findings reveal TP53 aberrations in 85.7% of del(5q) complex karyotype AML/MDS, suggesting challenges for venetoclax therapy.

Key Points

  • This study assessed the prevalence of TP53 aberrations in AML and MDS patients with del(5q) complex karyotypes.
  • Included patients from the NCI myeloMATCH trial between May 2024 to May 2025.
  • Analyzed karyotype, fluorescence in situ hybridization (FISH), chromosome genomic array testing (CGAT), and NMA results.
  • Categorized cytogenetics using ELN2017 guidelines to group patients.
  • 13.0% of 468 initial patients were excluded due to disqualifying diagnoses.
  • Karyotype abnormality in 59.0% and FISH abnormality in 50.0% of valid samples.
  • Biallelic TP53 aberrations were found in 85.7% of del(5q) complex cases with del(17p).

Cite This Study

Fang et al. (2025) studied this question.

synapsesocial.com/papers/693624984fa91c937236bff2https://doi.org/10.1182/blood-2025-5276
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes2025 · 1 citations
  2. 2Characteristics and prognostic implications of <i>TP53</i> mutations in Chinese patients with myelodysplastic syndromes2025 · 3 citations
  3. 3Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database2025
  4. 417p cytogenetic changes in TP53-mutated AML2025
  5. 5TP53-mutated Acute Myeloid Leukemia through a single-cell lens2025